Stockscreener 앱 받기
12.57
3.03%
0.37
시간 외 거래:
12.54
-0.03
-0.24%
전일 마감가:
$12.20
열려 있는:
$12.34
하루 거래량:
115.53K
Relative Volume:
0.76
시가총액:
$431.83M
수익:
$7,000
순이익/손실:
$-38.96M
주가수익비율:
-13.52
EPS:
-0.9296
순현금흐름:
$-18.34M
1주 성능:
+3.46%
1개월 성능:
+14.38%
6개월 성능:
+4.75%
1년 성능:
-9.57%
1일 변동 폭
$12.04
$12.70
1주일 범위
$11.41
$12.70
52주 변동 폭
$9.85
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
명칭
Benitec Biopharma Inc
전화
(510) 780-0819
주소
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
12.57 | 419.12M | 7,000 | -38.96M | -18.34M | -0.9296 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-09-12 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Leerink Partners | Outperform |
| 2024-06-13 | 개시 | Piper Sandler | Overweight |
| 2020-10-05 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | 개시 | Ladenburg Thalmann | Buy |
| 2016-02-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-12-31 | 재확인 | Maxim Group | Buy |
| 2015-09-16 | 재확인 | Maxim Group | Buy |
모두보기
Benitec Biopharma Inc 주식(BNTC)의 최신 뉴스
Trading the Move, Not the Narrative: (BNTC) Edition - Stock Traders Daily
BNTC Stock Price, Quote & Chart | BENITEC BIOPHARMA INC (NASDAQ:BNTC) - ChartMill
Benitec presents OPMD gene therapy data at May conference - Investing.com UK
Benitec presents OPMD gene therapy data at May conference By Investing.com - Investing.com India
Rare swallowing disease study posts 24-month follow-up at gene therapy meeting - Stock Titan
Benitec Biopharma Announces Oral Presentation of Interim - GlobeNewswire
Biotech founder behind a $14.6B sale joins Seaport board - Stock Titan
Biotech founder behind $14.6B sale joins Seaport board - Stock Titan
(BNTC) Volatility Zones as Tactical Triggers - Stock Traders Daily
Benitec (BNTC) Stock: Why Analysts Watch It (Breakout Watch) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Price-Driven Insight from (BNTC) for Rule-Based Strategy - Stock Traders Daily
Macro Review: How liquid is Benitec Biopharma Inc stock2026 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Quarterly Earnings: Does Benitec Biopharma Inc meet Warren Buffetts criteria2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Is Benitec Biopharma Inc part of any major index2026 Geopolitical Influence & High Return Trade Opportunity Guides - baoquankhu1.vn
Entry Recap: What is the Moat Score of Benitec Biopharma IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
Is Benitec (BNTC) Stock Priced Correctly | Price at $10.93, Up 0.05%Shared Trade Ideas - Newser
(BNTC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ideas Watch: How liquid is Benitec Biopharma Inc stockPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Sectors: Can Benitec Biopharma Inc maintain its current growth rate2026 Technicals & Weekly High Conviction Ideas - baoquankhu1.vn
Market Wrap: Is Benitec Biopharma Inc stock a buy or sellQuarterly Market Summary & AI Enhanced Trading Alerts - baoquankhu1.vn
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving Average – Here’s What Happened - Defense World
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(BNTC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Market Moves: Is Benitec Biopharma Inc forming a double bottom2026 Closing Moves & Verified Short-Term Plans - baoquankhu1.vn
BNTC SEC FilingsBenitec Biopharm 10-K, 10-Q, 8-K Forms - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) FY 2025 loss widens to $37.9M - Stock Titan
Benitec Biopharma | 10-K/A: Annual report (Amendment) - Moomoo
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Risk Recap: What is the dividend yield of Benitec Biopharma Inc2026 Setups & Low Drawdown Trading Strategies - baoquankhu1.vn
Portfolio Recap: Is Benitec Biopharma Inc stock a good dividend stockDollar Strength & High Accuracy Swing Trade Signals - baoquankhu1.vn
Jerel A. Banks, MD, PhD, on Evaluating Gene Therapy BB-301 for OPMD-Related Dysphagia - CGTLive®
Surprises Report: Can Benitec Biopharma Inc maintain its current growth rate2026 Fundamental Recap & Intraday High Probability Alerts - baoquankhu1.vn
(BNTC) Risk Channels and Responsive Allocation - Stock Traders Daily
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for - The Manila Times
Benitec Biopharma to Host Industry Forum Breakfast Event at - GlobeNewswire
Benitec Biopharma (NASDAQ:BNTC) Receives Buy Rating from HC Wainwright - Defense World
Breakfast talk to show OPMD swallowing gains from gene therapy BB-301 - Stock Titan
Benitec Biopharma Inc. (BNTC) Competitors - Meyka
Cowen Reiterates Buy on Benitec Biopharma (BNTC) March 2026 - Meyka
Benitec Biopharma : Corporate Presentation, March 2026 - marketscreener.com
Benitec BioPharma stock maintains Buy rating on positive trial data By Investing.com - Investing.com South Africa
Benitec BioPharma stock maintains Buy rating on positive trial data - Investing.com
BNTC: HC Wainwright & Co. Reiterates Buy Rating on Benitec Bioph - GuruFocus
Benitec reports interim results from gene therapy trial - Investing.com Nigeria
Benitec Biopharma (BNTC) Reports Encouraging Interim Results fro - GuruFocus
Benitec Biopharma Announces Positive Interim Phase 1b/2a - GlobeNewswire
Benitec's BB-301 delivers durable swallowing gains in OPMD - Stock Titan
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference - Bitget
Benitec Biopharma Stock Pre-Market (+7.1%): Analyst Raises EPS Forecasts - Trefis
Benitec Biopharma Inc (BNTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):